Front Endocrinol (Lausanne). 2025 Apr 28;16:1533748. doi: 10.3389/fendo.2025.1533748. eCollection 2025.
ABSTRACT
Type 1 diabetes (T1D) arises from an autoimmune attack on pancreatic beta cells, leading to a reliance on external insulin to maintain glucose levels. In recent years, research has increasingly focused on preventive strategies for individuals at high risk. A promising new intervention in this field is Teplizumab, the first approved disease-modifying therapy for T1D. Teplizumab is designed to delay progression to stage 3 T1D in adults and children aged 8 years and older who are diagnosed with stage 2 T1D.
PMID:40357199 | PMC:PMC12066327 | DOI:10.3389/fendo.2025.1533748